Filing Details
- Accession Number:
- 0001162956-14-000006
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-21 17:45:15
- Reporting Period:
- 2014-11-20
- Filing Date:
- 2014-11-21
- Accepted Time:
- 2014-11-21 17:45:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
926617 | Vermillion Inc. | VRML | In Vitro & In Vivo Diagnostic Substances (2835) | 330595156 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1162956 | T James Lafrance | C/O Vermillion, Inc. 12117 Bee Caves Rd Bldg 3 Ste 100 Austin TX 78738 | President & Chief Exec Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-11-20 | 27,907 | $1.44 | 78,022 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.40 to $1.49. The reporting person undertakes to provide to Vermillion, Inc. ("Vermillion"), any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.